Human Ace Co., Ltd. begins building a new drug development platform with ‘biomimetic chip’

by times news cr

2024-04-25 13:15:18

Ko Seong-ho, CEO of Human Ace Co., Ltd.

Utilizing biomimetic chip source technology to create a world without the need for animal testing

Human Ace Co., Ltd., an excellent company with Gachon University’s 2023 initial startup package, complements the limitations of 2D in-vitro cell culture technology and animal testing to create a world in which animal testing is not necessary when developing new drugs, and develops biotechnology that can produce results similar to clinical trials. It was announced on the 25th that it plans to build a new drug development platform using organ-on-chips.

Biomimetic chips are being developed as a next-generation technology to replace animal testing by imitating the main microstructure of organs inside a microchip and reflecting a system in which nutrients and drugs are supplied through blood vessels and are simultaneously discharged into blood vessels through metabolism.

Human Ace Co., Ltd. utilizes the original technology of biomimetic chips to replace animal testing when developing new drugs and to build a drug toxicity evaluation platform that can overcome the limitations of existing 2D cell culture experiments. Through many years of research, human , brain tissue chip development and technology are being advanced. In addition, we are expanding new pipelines by jointly researching chips modeling diseases such as pancreatic cancer, liver cancer, Alzheimer’s disease, Parkinson’s disease, and osteoporosis with universities, government-funded research institutes, and university hospitals.

Human Ace Co., Ltd. has laid the foundation for the development of biomimetic chip technology by graduating with the highest honors from the 2021 preliminary startup package and the 2023 initial startup package, which are the start-up commercialization support projects of the Ministry of SMEs and Startups and the Korea Institute of Entrepreneurship and Entrepreneurship Promotion. It has been selected as the ‘+1000 Project’ and is expected to receive up to 600 million won in support over three years.

Ko Seong-ho, CEO of Human Ace, said, “Research is currently underway to develop new drugs through animal testing, but the limitations of the agreement with clinical results are significantly low and ethical issues are emerging. “To overcome these problems, a new drug development platform that does not use animal testing must be developed when developing new drugs.”

CEO Ko continued, “If a new drug development platform is established in the future that can go beyond animal testing and cover clinical trials, new new drugs will be created quickly and quickly.” He added, “I want to create a world where all mankind can live long and healthy lives.” “He added.

Choi Yong-seok, Donga.com reporter [email protected]

Hot news now

2024-04-25 13:15:18

You may also like

Leave a Comment